Oscar Gallego Rubio

List of Publications by Year
in descending order

31 papers	**217** citations	1478458 **6** h-index	996954 **15** g-index
31 all docs	**31** docs citations	**31** times ranked	**558** citing authors

#	Article	IF	Citations
1	Is IDO1 an adequate target for treatment in glioblastoma?. Journal of Clinical Oncology, 2022, 40, e14039-e14039.	1.6	0
2	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP–negative Glioblastoma. Clinical Cancer Research, 2021, 27, 645-655.	7.0	5
3	Preservación de órgano tras un tratamiento con quimioterapia de inducción en pacientes con carcinomas localmente avanzados (T3-T4) de cavidad oral y orofaringe. Acta Otorrinolaringológica Española, 2021, 72, 27-36.	0.4	0
4	Gene fusions in glioblastoma: Results of Gliocat project.. Journal of Clinical Oncology, 2021, 39, 2042-2042.	1.6	0
5	Preservación de órgano en pacientes con tumores avanzados de laringe. Resultados de la quimioterapia de inducción versus quimio-radioterapia en la práctica clínica real. Acta Otorrinolaringológica Española, 2021, 72, 143-151.	0.4	0
6	Elderly glioblastoma patients: Survival analysis according adjuvant therapy and tumor molecular analysis.. Journal of Clinical Oncology, 2021, 39, e14046-e14046.	1.6	0
7	Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database.. Journal of Clinical Oncology, 2021, 39, e14047-e14047.	1.6	0
8	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. Clinical Cancer Research, 2020, 26, 6600-6609.	7.0	10
9	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro-Oncology, 2020, 22, 1851-1861.	1.2	64
10	Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project.. Journal of Clinical Oncology, 2019, 37, 2029-2029.	1.6	4
11	Risk of second primary neoplasia in patients with oropharyngeal carcinoma: Role of HPV status in the outcome.. Journal of Clinical Oncology, 2019, 37, e17544-e17544.	1.6	0
12	Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3064-3064.	1.6	24
13	Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Medicine, 2017, 6, 2858-2866.	2.8	44
14	Validation of the pathological classification of lymph node metastasis for head and neck tumors (HNSCC) according to the 8th edition of the TNM Classification of Malignant Tumors (8th TNM).. Journal of Clinical Oncology, 2017, 35, 6014-6014.	1.6	0
15	Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study).. Journal of Clinical Oncology, 2017, 35, e13526-e13526.	1.6	0
16	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	2.9	40
17	Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study.. Journal of Clinical Oncology, 2016, 34, 2045-2045.	1.6	1
18	Risk of distant metastases in head and neck carcinoma patients and myeloperoxidase (MPO) expression.. Journal of Clinical Oncology, 2016, 34, 6067-6067.	1.6	2

#	Article	IF	Citations
19	Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy—A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013.. Journal of Clinical Oncology, 2016, 34, e13515-e13515.	1.6	1
20	Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study.. Journal of Clinical Oncology, 2016, 34, e13513-e13513.	1.6	0
21	Expression of the CXCL12/CXCR4 chemokine axis as predictor of regional control in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2015, 33, e17093-e17093.	1.6	0
22	GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.. Journal of Clinical Oncology, 2014, 32, TPS2110-TPS2110.	1.6	1
23	Expression of interleukin-1α (IL1-α) and risk of distant metastases (DM) in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2014, 32, 6078-6078.	1.6	0
24	A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.. Journal of Clinical Oncology, 2014, 32, 2028-2028.	1.6	0
25	GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive high-grade glioma (HGG) in Spain.. Journal of Clinical Oncology, 2014, 32, 2055-2055.	1.6	0
26	Bevacizumab in combination with TMZ in patients with recurrent GBM: Final OS and PFS analysis.. Journal of Clinical Oncology, 2013, 31, 2087-2087.	1.6	1
27	Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.. Journal of Clinical Oncology, 2012, 30, 10052-10052.	1.6	3
28	A phase II multicentric study of sunitinib administered as upfront therapy in glioblastoma: A study by the GEINO group.. Journal of Clinical Oncology, 2012, 30, 2045-2045.	1.6	1
29	Progressive increasing in the risk of second and subsequent malignant tumors in patients with a head and neck cancer: A validation study with SEER data.. Journal of Clinical Oncology, 2012, 30, 5595-5595.	1.6	0
30	Gene expression as a predictor of radiotherapy or chemoradiotherapy response in head and neck squamous cell carcinoma patients: A molecular approach.. Journal of Clinical Oncology, 2012, 30, 5590-5590.	1.6	0
31	What can nanotechnology do to fight cancer?. Clinical and Translational Oncology, 2006, 8, 788-795.	2.4	16